-
EP3717077
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3717077
| EP3717077 - METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 25.11.2022 Database last updated on 22.08.2024 | |
| Former | Request for examination was made Status updated on 04.09.2020 | ||
| Former | The international publication has been made Status updated on 07.06.2019 | ||
| Former | unknown Status updated on 14.12.2018 | Most recent event Tooltip | 23.05.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Robert-Rössle-Straße 10 13125 Berlin / DE | [N/P] |
| Former [2020/41] | For all designated states Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Robert-Rössle-Strasse 10 13125 Berlin / DE | Inventor(s) | 01 /
BADER, Michael Strasse 45 35 13125 Berlin / DE | 02 /
QADRI, Fatimunnisa Röländer Str. 30 13125 Berlin / DE | 03 /
TODIRAS, Mihail Constantin Virnav Str. 21/1, ap.12 Chisinau, 2025 / MD | 04 /
ALENINA, Natalia Strasse 50 48 13125 Berlin / DE | [2020/41] | Representative(s) | Hertin und Partner Rechts- und Patentanwälte PartG mbB Kurfürstendamm 54/55 10707 Berlin / DE | [2020/41] | Application number, filing date | 18811796.4 | 29.11.2018 | [2020/41] | WO2018EP82997 | Priority number, date | EP20170204424 | 29.11.2017 Original published format: EP 17204424 | [2020/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019106085 | Date: | 06.06.2019 | Language: | EN | [2019/23] | Type: | A1 Application with search report | No.: | EP3717077 | Date: | 07.10.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.06.2019 takes the place of the publication of the European patent application. | [2020/41] | Search report(s) | International search report - published on: | EP | 06.06.2019 | Classification | IPC: | A61Q19/02, A61Q19/04, A61K31/655, A61P35/00, A61P17/00, A61K31/00, A61K8/35, A61K8/40 | [2020/41] | CPC: |
A61P17/00 (EP);
A61K8/4946 (US);
A61K31/4174 (EP);
A61K31/655 (EP);
A61K38/34 (EP);
A61K45/06 (EP);
A61K8/35 (EP);
A61K8/40 (EP);
A61K8/411 (US);
A61K8/64 (EP);
A61K9/0014 (EP);
A61K9/70 (EP);
A61P35/00 (EP);
A61Q17/04 (US);
A61Q19/00 (EP);
A61Q19/004 (EP);
A61Q19/02 (EP,US);
A61Q19/04 (US);
A61Q5/08 (US);
A61Q5/10 (EP,US);
C12N9/485 (EP);
| C-Set: |
A61K31/4174, A61K2300/00 (EP);
A61K31/655, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/41] | Title | German: | VERFAHREN ZUR MODULATION DER PIGMENTIERUNG DURCH ANGIOTENSIN-KONVERTIERENDE ENZYM-2-MODULATION | [2020/41] | English: | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | [2020/41] | French: | MÉTHODE VISANT À MODULER LA PIGMENTATION PAR MODULATION DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE 2 | [2020/41] | Entry into regional phase | 25.05.2020 | National basic fee paid | 25.05.2020 | Designation fee(s) paid | 25.05.2020 | Examination fee paid | Examination procedure | 25.05.2020 | Examination requested [2020/41] | 25.05.2020 | Date on which the examining division has become responsible | 13.01.2021 | Amendment by applicant (claims and/or description) | 24.11.2022 | Despatch of a communication from the examining division (Time limit: M04) | 28.03.2023 | Reply to a communication from the examining division | 22.05.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 08.10.2020 | Renewal fee patent year 03 | 03.11.2021 | Renewal fee patent year 04 | 18.10.2022 | Renewal fee patent year 05 | 12.10.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XA]WO0239997 (MILLENNIUM PHARM INC [US], et al) [X] 22,23,25 * claims 29-35 * * paragraph [0111] - paragraph [0116] * [A] 1-21,24,26-45; | [XA]US2004082496 (ACTON SUSAN L [US], et al) [X] 22,23,25 * claims 1-71 * [A] 1-21,24,26-45; | [IY]WO2005072696 (ACE APS [DK], et al) [I] 1-26 * the whole document * [Y] 27-45; | [XA]WO2008066770 (UNIV FLORIDA [US], et al) [X] 22,25 * the whole document * [A] 1-21,23,24,26-45; | [YA]AT506632 (APEIRON BIOLOG FORSCHUNGS UND [AT]) [Y] 27-45 * claim 2 * * page 10 - page 13 *[A] 1-26; | [XDA]US2010204286 (DONAHUE STEPHEN R [US], et al) [XD] 22,23 * the whole document * [A] 1-21,24-45; | [YA] - TAO LIFEI ET AL, "Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-kappa B pathways in human retinal pigment epithelium", JOURNAL OF NEUROINFLAMMATION, (20160209), vol. 13, ISSN 1742-2094, XP009511451 [Y] 27-45 * abstract * [A] 1-26 DOI: http://dx.doi.org/10.1186/s12974-016-0489-7 | by applicant | US6632830 | US2004082496 | WO2008066770 | WO2010093804 | EP2332582 | WO2018140456 | - HERNANDEZ PRADA et al., Hypertension, (20080000), vol. 51, pages 1312 - 1317 | - Journal of Biomolecular Screening, (20110000), vol. 16, pages 878 - 885 | - SHENOY et al., Am J Respir Crit Care Med, (20130315), vol. 187, no. 6, pages 648 - 657 | - OSTROV, Journal of Biomolecular Screening, (20110000), vol. 16, pages 878 - 885 | - HUANG et al., The Journal of Biological Chemistry, (20030502), vol. 278, no. 18, pages 15532 - 15540 | - MORES et al., J. Med. Chem., (20080000), vol. 51, pages 2216 - 2226 | - KULEMINA; OSTROV, Journal of Biomolecular Screening, (20110000), vol. 16, pages 878 - 885 | - ABDEL-MALEK ZA; SWOPE VB; STARNER RJ; KOIKOV L; CASSIDY P, "Leachman S. Melanocortins and the melanocortin 1 receptor, moving translationally towards melanoma prevention", Arch Biochem Biophys, (20140000), vol. 563, doi:doi:10.1016/j.abb.2014.07.002, pages 4 - 12, XP029093594 DOI: http://dx.doi.org/10.1016/j.abb.2014.07.002 | - BADER M., "ACE2, Angiotensin-(1-7), and Mas: The other side of the coin", Pflügers Arch., (20130000), vol. 465, pages 79 - 85 | - BIBA E, "Protection: the sunscreen pill", Nature, (20141120), vol. 515, no. 7527, pages 124 - 5 | - CAHN A; CERNEA S; RAZ I, "An update on DPP-4 inhibitors in the management of type 2 diabetes", Expert Opin Emerg Drugs, (20161200), vol. 21, no. 4, pages 409 - 419 | - CAMPBELL DJ, "Long-term neprilysin inhibition - implications for ARNIs", Nat Rev Cardiol., (20170300), vol. 14, no. 3, pages 171 - 186 | - DALES NA; GOULD AE; BROWN JA; CALDERWOOD EF; GUAN B; MINOR CA; GAVIN JM; HALES P; KAUSHIK VK; STEWART M, "Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors", J Am Chem Soc., (20021009), vol. 124, no. 40, doi:doi:10.1021/JA0277226, pages 11852 - 3, XP002530093 DOI: http://dx.doi.org/10.1021/JA0277226 | - ERICSON MD; LENSING CJ; FLEMING KA; SCHLASNER KN; DOERING SR; HASKELL-LUEVANO C, "Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016", Biochim Biophys Acta, (20170329), vol. S0925-44, no. 17, pages 30107 - 2 | - GRZEGRZOLKA J; SWIATKO K; PULA B; ZAMIRSKA A; OLBROMSKI M; BIENIEK A; SZEPIETOWSKI J; RYS J; DZIEGIEL P, "Podhorska-Okolow M. ACE and ACE2 expression in normal and malignant skin lesions", Folia Histochem Cytobiol., (20130000), vol. 51, no. 3, pages 232 - 8 | - HAMMING I; TIMENS W; BULTHUIS ML; LELY AT; NAVIS G; VAN GOORH, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus", A first step in understanding SARS pathogenesis. J Pathol., (20040000), vol. 203, pages 631 - 7 | - HERPIN TF; YU G; CARLSON KE; MORTON GC; WU X; KANG L; TUERDI H; KHANNA A; TOKARSKI JS; LAWRENCE RM, "Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties", J Med Chem., (20030327), vol. 46, no. 7, doi:doi:10.1021/jm025600i, pages 1123 - 6, XP002343917 DOI: http://dx.doi.org/10.1021/jm025600i | - HUANG L; SEXTON DJ; SKOGERSON K; DEVLIN M; SMITH R; SANYAL I; PARRY T; KENT R; ENRIGHT J; WU QL, "Novel peptide inhibitors of angiotensin-converting enzyme 2", J Biol Chem, (20030502), vol. 278, no. 18, pages 15532 - 40 | - JEONG JK; DIANO S, "Prolyl carboxypeptidase and its inhibitors in metabolism", Trends Endocrinol Metab., (20130000), vol. 24, doi:doi:10.1016/j.tem.2012.11.001, pages 61 - 7, XP055096997 DOI: http://dx.doi.org/10.1016/j.tem.2012.11.001 | - KANG L; MCLNTYRE KW; GILLOOLY KM; YANG Y; HAYCOCK J; ROBERTS S; KHANNA A; HERPIN TF; YU G; WU X, "A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice", J Leukoc Biol., (20061000), vol. 80, no. 4, pages 897 - 904 | - LINDSKOG JONSSON A; GRANQVIST A; ELVIN J; JOHANSSON ME; HARALDSSON B; NYSTROM J, "Effects of melanocortin 1 receptor agonists in experimental nephropathies", PLoS One, (20140130), vol. 9, no. 1, page e87816 | - MAIER C; SCHADOCK I; HABER PK; WYSOCKI J; YE M; KANWAR Y; FLASK CA; YU X; HOIT BD; ADAMS GN, "Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II", J Mol Med (Berl, (20170000), vol. 95, no. 5, doi:doi:10.1007/s00109-017-1513-9, pages 473 - 486, XP036219377 DOI: http://dx.doi.org/10.1007/s00109-017-1513-9 | - MINDER EL; BARMAN-AKSOEZEN J; SCHNEIDER-YIN X, "Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders", Clin Pharmacokinet, (20170106), vol. 10, no. 1007, pages s40262 - 016,0501-5 | - MOTTA-SANTOS D; DOS SANTOS RA; OLIVEIRA M; QADRI F; POGLITSCH M; MOSIENKO V; KAPPES BL; CAMPAGNOLE-SANTOS MJ; PENNINGER M; ALENINA, "Effects of ACE2 deficiency on physical performance and physiological adaptations of cardiac and skeletal muscle to exercise", Hypertens Res, (20160000), vol. 39, pages 506 - 512 | - NUNES-SOUZA V; ALENINA N; QADRI F; PENNINGER JM; SANTOS RA; BADER M; RABELO LA, "CD36/Sirtuin 1 Axis Impairment Contributes to Hepatic Steatosis in ACE2-Deficient Mice", Oxid Med Cell Longev 2016, (20160000), page 6487509 | - PAUS R, "A neuroendocrinological perspective on human hair follicle pigmentation", Pigment Cell Melanoma Res, (20110200), vol. 24, no. 1, pages 89 - 106 | - RABELO LA; TODIRAS M; NUNES-SOUZA V; QADRI F; SZIJARTO IA; GOLLASCH M; PENNINGER JM; BADER M; SANTOS RA; ALENINA N, "Genetic Deletion of ACE2 Induces Vascular Dysfunction in C57BL/6 Mice: Role of Nitric Oxide Imbalance and Oxidative Stress", PLoS One, (20160000), vol. 11, page e0150255 | - RENTZSCH B; TODIRAS M; LLIESCU R; POPOVA E; CAMPOS LA; OLIVEIRA ML; BALTATU OC; SANTOS RA; BADER M, "Transgenic ACE2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function", Hypertension, (20080000), vol. 52, pages 967 - 97 | - SHAH PP; DESAI PR; BOAKYE CH; PATLOLLA R; KIKWAI LC; BABU RJ; SINGH M, "Percutaneous delivery of a-melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis", J Drug Target, (20160000), vol. 24, no. 6, pages 537 - 47 | - VICKERS C; HALES P; KAUSHIK V; DICK L; GAVIN J; TANG J; GODBOUT K; PARSONS T; BARONAS E; HSIEH F, "Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase", J Biol Chem., (20020426), vol. 277, no. 17, doi:doi:10.1074/jbc.M200581200, pages 14838 - 43, XP002464545 DOI: http://dx.doi.org/10.1074/jbc.M200581200 | - WALLINGFORD N; PERROUD B; GAO Q; COPPOLA A; GYENGESI E; LIU ZW; GAO XB; DIAMENT A; HAUS KA; SHARIAT-MADAR Z, "Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents", J Clin Invest, (20090800), vol. 119, no. 8, doi:doi:10.1172/JCI37209, pages 2291 - 303, XP008158089 DOI: http://dx.doi.org/10.1172/JCI37209 |